Pirro Hysi

Dr. Pirro Hysi is a Reader (equivalent to Associate Professor) in Ophthalmology at King's College London, where he serves as School Academic Lead for Postgraduate Research within the School of Life Course & Population Sciences. His work bridges genetics, genomics, and ophthalmology, with a focus on understanding the genetic basis of eye diseases and related conditions.

Dr. Hysi's research spans multiple areas of genetic ophthalmology and population genomics. His work primarily focuses on genome-wide association studies (GWAS) to identify genetic variants associated with eye conditions including myopia, glaucoma, keratoconus, and age-related macular degeneration. He also investigates the intersection of genetics with metabolomics, exploring how metabolic pathways influence ocular health and disease progression. His research has expanded into machine learning applications for disease prediction and the genetic basis of systemic conditions that impact eye health.

His publication record demonstrates a strong focus on large-scale genetic studies, often leveraging data from the UK Biobank and other international cohorts. Recent work has expanded into applying machine learning approaches to predict disease progression and exploring the genetic basis of conditions beyond ophthalmology, including cardiovascular health, metabolic disorders, and pregnancy-related conditions.

Dr. Hysi serves as Principal Investigator or Co-Investigator on multiple research projects funded by organizations including Fight for Sight, the BrightFocus Foundation, NIH, and the Fetal Medicine Foundation. His current projects include investigating metabolic factors in age-related eye diseases, developing vision measurement technology, and identifying glaucoma therapy targets through multi-omic analysis.

He is actively involved in several major research consortia, particularly the UK Biobank Eye and Vision Consortium, and has contributed to numerous large-scale genetic studies across multiple medical specialties. His work has been featured in high-impact journals including Nature Communications, JAMA Ophthalmology, and Nature Medicine.